Report Description Table of Contents How Are Conservative Care, Non-Opioid Therapies, and Minimally Invasive Interventions Reshaping the Sciatica Treatment Market? – (Updated On: 5th-Oct-2026) The Global Sciatica Treatment Market was valued at USD 5.47 billion in 2025 and is projected to reach USD 9.05 billion by 2032, expanding at a CAGR of 7.46% during 2026–2032. Sciatica affects a large treatment population, with lifetime prevalence estimates ranging from roughly 13% to 40%, while annual incidence is commonly estimated at about 1%–5%. In the United States, approximately 40% of people may experience sciatica at some point in their lives, creating a recurring need for pain management, rehabilitation and interventional treatment. The market is shaped heavily by the fact that most patients are treated without surgery. An estimated 80%–90% of cases improve with conservative care, often within 4–6 weeks. This keeps physical therapy, NSAIDs and other non-opioid pain-management approaches at the center of early treatment. Use of gabapentin and pregabalin remains common for neuropathic symptoms, although clinical evidence for sciatica is mixed, limiting their role as a universal solution. Patients with persistent or severe radicular pain create the main opportunity for interventional treatment. Epidural steroid injections are widely used when conservative therapy does not provide sufficient relief, while selected patients with structural nerve compression may eventually undergo procedures such as microdiscectomy. Surgical success rates of roughly 75%–90% in appropriately selected patients support surgery as an important later-stage option, but it remains relevant to a smaller patient group than non-surgical care. The market is therefore moving toward a staged treatment model: conservative therapy first, non-opioid pharmacological management next, minimally invasive intervention for persistent symptoms, and surgery for selected refractory cases. Revenue growth through 2032 will depend on the large pool of recurrent and persistent patients who progress beyond basic self-care into specialist pain-management and interventional services. Why Is Chronic Sciatica Leading Revenue While Targeted Interventions Create New Growth Opportunities? By Sciatica Type Leading Subsegment – Chronic Sciatica Chronic sciatica represents approximately 63% of the Sciatica Treatment Market, generating nearly USD 3.45 billion in 2025 revenue, and is projected to advance at a 7.75% CAGR during 2026–2032. Persistent symptoms shift clinical management beyond temporary pain and inflammation control toward longer-term treatment of nerve irritation and underlying spinal conditions. This sustained care pathway increases the use of prescription therapies, physical rehabilitation, epidural interventions, and selected surgical procedures, creating recurring treatment activity across specialist and multidisciplinary care settings. By Pharmacological Therapy Leading Subsegment – Non-Steroidal Anti-Inflammatory Drugs NSAIDs account for approximately 39% of pharmacological treatment value in the Sciatica Treatment Market, equivalent to USD 2.13 billion in 2025, and are projected to advance at a 5.85% CAGR during 2026–2032. Drugs such as ibuprofen and naproxen remain widely used as an early conservative option to reduce inflammation around the sciatic nerve. However, evidence of limited direct pain relief versus placebo is keeping NSAIDs positioned mainly for short-term symptom management rather than long-term sciatica control. Fastest-Growing Subsegment – Emerging Biologics & Regenerative/Targeted Injectables Emerging biologics, regenerative therapies, and targeted injectables accounted for an estimated 14% of the Sciatica Treatment Market, equivalent to approximately USD 0.77 billion in 2025, and are projected to advance at a 12.25% CAGR during 2026–2032. These therapies are reshaping sciatica management by moving treatment beyond temporary inflammation control toward biological repair, tissue regeneration, and targeted immunomodulation, particularly for persistent nerve irritation and structural damage where conventional epidural steroid injections may provide only short-term symptom relief. By Non-Pharmacological Treatment Modality Leading Subsegment – Physical & Exercise Therapy Physical and exercise therapy accounts for approximately 34% of the Sciatica Treatment Market, equivalent to USD 1.86 billion in 2025, and is projected to advance at a 7.55% CAGR during 2026–2032. Its strong position reflects its role as a primary non-invasive approach for reducing sciatic nerve compression, restoring mobility, improving spinal and muscular function, and lowering the risk of recurring flare-ups, particularly among patients managed without surgery or long-term pharmacological intervention. Fastest-Growing Subsegment – Radiofrequency Ablation & Neuromodulation Radiofrequency ablation (RFA) and neuromodulation, including spinal cord stimulation, account for an estimated 20% of the Sciatica Treatment Market, representing approximately USD 1.09 billion in 2025. These minimally invasive interventions are increasingly used for patients with chronic or treatment-resistant sciatica when physical therapy, medications, or steroid injections provide inadequate pain relief. The segment is projected to expand at approximately 10.45% CAGR, reflecting wider clinical use of targeted pain-management procedures that interrupt or modify persistent sciatic nerve pain signals. By Route of Administration Leading Subsegment – Oral Delivery Oral therapies account for approximately 57% of the Sciatica Treatment Market, equivalent to USD 3.12 billion in 2025, and are projected to expand at a 5.95% CAGR during 2026–2032. Their large market position reflects their foundational role as a first-line option for acute sciatica, where oral medications are widely prescribed to reduce systemic inflammation and relieve sharp, radiating nerve pain. Their accessibility, non-invasive administration, and suitability for initial symptom management keep them central to sciatica treatment pathways. Fastest-Growing Subsegment – Parenteral/Epidural Injection Parenteral and epidural administration accounted for approximately 28% of the Sciatica Treatment Market, representing USD 1.53 billion in 2025, and is projected to advance at a 9.65% CAGR during 2026–2032, the fastest among administration routes. Epidural steroid injections deliver corticosteroids and anesthetics directly into the spinal epidural space, helping reduce nerve-root inflammation and radiating sciatic pain. Their targeted action and use in persistent cases support wider clinical adoption when oral therapies provide inadequate symptom relief. By End User Leading Subsegment – Hospitals & Associated Pharmacies Hospitals and associated pharmacies account for approximately 39% of the Sciatica Treatment Market, representing USD 2.13 billion in 2025 revenue, and are projected to expand at a 6.85% CAGR during 2026–2032. Hospitals support demand through diagnostic imaging, acute pain management, epidural injections, surgical procedures, and rehabilitation services for severe or persistent sciatica. Associated pharmacies strengthen treatment access by dispensing NSAIDs, muscle relaxants, neuropathic pain medicines, and other prescribed therapies while providing medication counseling and ongoing support for patients. Fastest-Growing Subsegment – Home-Care Settings & Online Providers Hospitals and associated pharmacies accounted for approximately 39% of the Sciatica Treatment Market, representing USD 2.13 billion in 2025, and are projected to expand at a CAGR of 6.85% during 2026–2032. Their strong market position reflects the ability to provide multi-tiered sciatica care, ranging from medication-based symptom management and epidural injections to advanced interventional procedures, specialist consultation, and surgical evaluation, making hospitals a central treatment setting for patients with persistent, severe, or treatment-resistant sciatic pain. By Geography Leading Subsegment – North America North America accounted for approximately 40% of the Sciatica Treatment Market, representing nearly USD 2.19 billion in 2025, and is projected to expand at a 6.75% CAGR during 2026–2032. The region’s strong position is supported by an aging population, rising prevalence of chronic lower-back and nerve-related pain, and wider access to specialized pain-management services. Increasing use of minimally invasive procedures, image-guided injections, radiofrequency therapies, and neuromodulation is further expanding treatment options for patients with persistent or recurrent sciatica. Fastest-Growing Subsegment – Asia-Pacific Asia-Pacific accounted for an estimated 25% of the Sciatica Treatment Market, valued at approximately USD 1.37 billion in 2025, and is projected to expand at the fastest regional CAGR of around 10.25% during 2026–2032. Sciatica care across the region is shifting from self-managed pain relief and traditional therapies toward integrated treatment pathways combining medication, physiotherapy, epidural injections, and minimally invasive procedures. Wider specialist access and improving pain-management infrastructure are accelerating the adoption of structured sciatica treatment across major Asia-Pacific countries. How Are Sciatica-Specific Drug Development and Neuromodulation Reshaping the Competitive Landscape? Semnur Pharmaceuticals / Scilex Holding – Advancing a Sciatica-Specific Non-Opioid Injectable Semnur Pharmaceuticals, operating within the Scilex ecosystem, stands out because its lead candidate SEMDEXA (SP-102) is being developed specifically for lumbosacral radicular pain/sciatica, rather than for generalized chronic pain. SP-102 is a viscous dexamethasone sodium phosphate formulation designed for transforaminal epidural administration, positioning the company directly in the shift toward targeted, non-opioid treatment. Its pivotal Phase III CLEAR trial enrolled 401 patients with sciatica across more than 40 U.S. clinical sites. The trial evaluated a single epidural transforaminal injection and included follow-up extending to 24 weeks. Scilex states that SP-102 could become the first FDA-approved epidural steroid injection product specifically for sciatica if ultimately approved, giving the program potentially strong first-mover relevance in a treatment area where epidural steroids are widely used but products are not specifically approved for this indication. Boston Scientific – Building a Strong Position in Chronic Radicular Pain Through Advanced Spinal Cord Stimulation Boston Scientific is a major technology leader in the interventional side of the Sciatica Treatment Market through its WaveWriter Alpha spinal cord stimulation platform. Its systems are indicated for chronic intractable pain including radicular pain syndrome, radiculopathy associated with herniated disc, and chronic low-back and leg pain, making the technology directly relevant to persistent sciatica-like pain that does not respond adequately to conservative treatment. The company's FAST sub-perception stimulation technology is supported by multiple randomized and real-world studies. In one real-world analysis of 289 patients, average pain scores declined from 7.8 to 2.3, while 91% achieved at least 50% pain reduction; patients receiving FAST therapy experienced meaningful relief within an average of 2.6 minutes after activation. Boston Scientific also reports 5.0–5.6-point pain-score reductions maintained for two years in longer-term FAST studies. These outcomes support its positioning in high-value, refractory chronic radicular pain rather than routine first-line sciatica management. Other Important Companies and Their Roles Medtronic: Provides DTM™ spinal cord stimulation systems for chronic intractable back and limb pain, including radicular pain associated with herniated discs; its NOVA study reported a mean leg-pain VAS score of 1.28 at 12 months with DTM SCS. Abbott: Competes through the Proclaim™ XR spinal cord stimulation platform, targeting chronic intractable low-back and leg pain with implantable neurostimulation technology. Pfizer: Participates through established neuropathic-pain pharmaceuticals such as pregabalin, although gabapentinoids are no longer favored by some major guidelines for routine sciatica treatment. Teva Pharmaceutical Industries: Supports the lower-cost medication segment through generic pain-management products, including commonly prescribed anti-inflammatory and neuropathic-pain medicines. Nevro: Competes in advanced chronic pain management through high-frequency spinal cord stimulation technologies used in persistent back and leg pain patients. What Are the Key Drivers Accelerating Growth in the Sciatica Treatment Market? Rising burden of lumbar disc herniation and chronic radicular pain: Lumbar disc herniation remains the principal structural cause of sciatica, accounting for an estimated 85–90% of cases involving nerve-root compression or inflammation. The commercial impact is amplified by persistence: around 20–30% of patients can continue experiencing symptoms after one year, creating repeat demand for medication, rehabilitation, injections and specialist care. Aging populations are expanding the addressable patient base: Degenerative spinal changes, lumbar stenosis and disc disease become more common with age, increasing the number of patients requiring long-term sciatica management. This particularly supports demand in mature healthcare markets where older populations have greater access to imaging, pain clinics, rehabilitation and minimally invasive spine procedures. Shift away from prolonged opioid and gabapentinoid use: Clinical guidelines are increasingly discouraging routine long-term use of opioids, gabapentinoids, oral corticosteroids and benzodiazepines for sciatica where sustained benefit is limited. This is redirecting treatment spending toward physical therapy, NSAIDs used cautiously, targeted epidural treatment, decompression procedures and neuromodulation, creating opportunities for non-opioid therapies and device-based interventions. Expansion of minimally invasive and outpatient treatment: Patients with persistent symptoms increasingly have access to image-guided epidural injections, microdiscectomy, endoscopic decompression and neuromodulation instead of traditional open surgery. These approaches can reduce hospital stay and recovery time, supporting higher procedure volumes in outpatient and specialty spine settings. Growth of sciatica-specific non-opioid drug development: Pipeline activity is becoming more targeted. Semnur Pharmaceuticals/Scilex's SEMDEXA (SP-102) completed a Phase III trial involving 401 patients across more than 40 U.S. sites, demonstrating the commercial interest in localized injectable therapies specifically designed for lumbosacral radicular pain. Greater use of MRI and specialist diagnosis: Wider access to lumbar MRI and specialist assessment enables physicians to identify nerve-root compression more precisely and select patients for injections or surgery. Better diagnostic stratification can move patients more quickly from generalized pain treatment toward procedure-specific care. Higher prevalence of obesity, prolonged sitting and occupational spinal loading: Higher BMI, smoking, repetitive bending and manual handling are recognized risk factors for lumbar disc herniation with radiculopathy. Increasing sedentary work and physically demanding occupations therefore continue to feed the incident and recurrent sciatica population. Expansion of rehabilitation and home-based care: Physical therapy remains central to conservative management, while tele-rehabilitation, remote exercise programs and home-based recovery are widening access to longer-duration care. This supports recurring revenue beyond pharmaceuticals and hospital-based treatment. Analyst Commentary: What Will Move Sciatica Care Beyond Prolonged Symptom Control? The Sciatica Treatment Market is moving away from prolonged symptom control toward treatment strategies that target the underlying source of radicular pain more directly. The strongest commercial opportunities are emerging around non-opioid epidural therapies, minimally invasive decompression, neuromodulation, structured rehabilitation, and technology-enabled outpatient care. Sciatica Treatment Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 5.47 Billion Revenue Forecast in 2032 USD 9.05 Billion Overall Growth Rate CAGR of 7.46% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Sciatica Type, By Pharmacological Therapy, By Non-Pharmacological Treatment Modality, By Route of Administration, By End User, By Geography By Sciatica Type Chronic Sciatica, Acute Sciatica By Pharmacological Therapy Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Neuropathic Pain Agents, Corticosteroids, Opioids, Emerging Biologics and Regenerative/Targeted Injectables By Non-Pharmacological Treatment Modality Physical & Exercise Therapy, Epidural Steroid Injections, Radiofrequency Ablation & Spinal Cord Stimulation, Surgical Interventions By Route of Administration Oral Delivery, Parenteral / Epidural Injection, Topical & Transdermal Systems By End User Hospitals & Associated Pharmacies, Specialty Pain Clinics & Rehabilitation Centers, Home-Care Settings & Online Providers By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Large global sciatica patient population, high prevalence of lumbar disc-related nerve compression, continued demand for conservative care, rising use of non-opioid pain-management approaches, expansion of epidural and minimally invasive interventions, increasing adoption of neuromodulation, growth of rehabilitation services, and development of targeted biologics and regenerative injectables Customization Option Available upon request Frequently Asked Question About This Report Q1: What are the main factors driving growth in the market? A1: Growth is being supported by the large population with recurrent sciatica, rising lumbar disc disease, and wider use of rehabilitation and minimally invasive pain treatments. Greater access to specialist diagnosis is also moving more patients into structured care. Q2: What are the key trends shaping the industry? A2: The industry is shifting away from prolonged symptom control toward non-opioid therapies, image-guided injections, neuromodulation, and minimally invasive decompression. Home rehabilitation and digital care are also becoming more important. Q3: Why are minimally invasive treatments gaining importance in the market? A3: Minimally invasive treatments are gaining attention because they offer options for patients who do not respond adequately to medication or physical therapy. Epidural injections, radiofrequency procedures, and spinal cord stimulation can provide targeted treatment without immediate open surgery. Q4: How is changing treatment practice influencing the industry? A4: Clinical practice is placing greater emphasis on physical therapy and cautious use of non-opioid medicines. At the same time, long-term reliance on opioids and gabapentinoids is becoming less favored, encouraging greater use of targeted interventions. Q5: Which region is expected to record the fastest growth in the market? A5: Asia-Pacific is projected to record the fastest regional CAGR of about 10.25% during 2026–2032. Growth is supported by aging populations, expanding spine-care infrastructure, and improving access to rehabilitation and interventional pain services. Q6: What new developments could influence the industry over the next few years? A6: Sciatica-specific epidural therapies, regenerative injectables, neuromodulation, and less invasive decompression procedures could reshape treatment. Pipeline products such as SEMDEXA also show growing interest in therapies developed specifically for radicular pain. Sources: NCBI – Sciatica: Conservative Management, 4–6 Week Recovery and Surgical Outcomes NCBI Sciatica Review NICE – Low Back Pain and Sciatica Guidelines: NSAIDs, Gabapentinoids, Opioids, Epidural Injections and Decompression Surgery NICE Sciatica Treatment Guidelines NCBI – NERVES Trial: Sciatica Prevalence, Disc Herniation, Epidural Steroid Injection and Microdiscectomy NCBI NERVES Sciatica Trial PubMed/PMC – Phase III CLEAR Trial of SEMDEXA (SP-102) for Lumbosacral Radicular Pain SEMDEXA Phase III Clinical Study U.S. SEC / Scilex – SEMDEXA Phase III CLEAR Trial: 401 Sciatica Patients Across 40+ U.S. Sites Scilex SEMDEXA Clinical Development Boston Scientific – FAST Therapy With WaveWriter Alpha: 289-Patient Real-World Pain Outcomes Boston Scientific FAST Therapy Clinical Data Boston Scientific – WaveWriter Alpha SCS Indications Including Radicular Pain and Herniated-Disc Radiculopathy Boston Scientific Spinal Cord Stimulation Medtronic – NOVA Study: DTM Spinal Cord Stimulation for Radicular Pain and Herniated Disc Medtronic NOVA Study NCBI – Lumbar Disc Herniation: 85–90% Resolve Within 6–12 Weeks Without Major Intervention NCBI Lumbar Disc Herniation Review Table of Contents - Global Sciatica Treatment Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Sciatica Type, Pharmacological Therapy, Non-Pharmacological Treatment Modality, Route of Administration, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Sciatica Type, Pharmacological Therapy, Non-Pharmacological Treatment Modality, Route of Administration, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Sciatica Type, Pharmacological Therapy, Non-Pharmacological Treatment Modality, Route of Administration, and End User Investment Opportunities in the Sciatica Treatment Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Non-Opioid Pain Management, Physical & Exercise Therapy, Epidural Steroid Injections, Neuromodulation, Minimally Invasive Spinal Procedures, and Targeted Regenerative Injectables Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Conservative Care, Non-Opioid Therapies, Rehabilitation, Minimally Invasive Interventions, and Selected Surgical Treatment in Sciatica Management Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Clinical Guidelines and Treatment Pathway Evolution Role of Conservative Care, Non-Opioid Pharmacological Management, Epidural Intervention, Neuromodulation, Rehabilitation, and Minimally Invasive Spinal Procedures in Market Expansion Shift Away from Prolonged Opioid and Gabapentinoid Use Toward Targeted, Multimodal, and Outpatient Sciatica Management Global Sciatica Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Sciatica Type: Chronic Sciatica Acute Sciatica Market Analysis by Pharmacological Therapy: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Neuropathic Pain Agents Corticosteroids Opioids Emerging Biologics and Regenerative/Targeted Injectables Market Analysis by Non-Pharmacological Treatment Modality: Physical & Exercise Therapy Epidural Steroid Injections Radiofrequency Ablation & Spinal Cord Stimulation Surgical Interventions Market Analysis by Route of Administration: Oral Delivery Parenteral / Epidural Injection Topical & Transdermal Systems Market Analysis by End User: Hospitals & Associated Pharmacies Specialty Pain Clinics & Rehabilitation Centers Home-Care Settings & Online Providers Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Sciatica Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Sciatica Type, Pharmacological Therapy, Non-Pharmacological Treatment Modality, Route of Administration, and End User Country-Level Breakdown: United States Canada Mexico Europe Sciatica Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Sciatica Type, Pharmacological Therapy, Non-Pharmacological Treatment Modality, Route of Administration, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Sciatica Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Sciatica Type, Pharmacological Therapy, Non-Pharmacological Treatment Modality, Route of Administration, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Sciatica Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Sciatica Type, Pharmacological Therapy, Non-Pharmacological Treatment Modality, Route of Administration, and End User Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Sciatica Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Sciatica Type, Pharmacological Therapy, Non-Pharmacological Treatment Modality, Route of Administration, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Semnur Pharmaceuticals / Scilex Holding Boston Scientific Corporation Medtronic plc Abbott Laboratories Pfizer Inc. Teva Pharmaceutical Industries Ltd. Nevro Corp. Stryker Corporation Johnson & Johnson MedTech (DePuy Synthes) Globus Medical, Inc. Zimmer Biomet Holdings, Inc. Competitive Landscape and Strategic Insights Benchmarking Based on Non-Opioid Therapy Portfolio, Interventional Pain Management Capabilities, Neuromodulation Technology, Minimally Invasive Spine Solutions, Rehabilitation Reach, and Regional Presence Therapeutic Pipeline and Clinical Development Capability Analysis Targeted Non-Opioid and Regenerative Injectable Positioning Epidural Intervention, Radiofrequency Ablation, and Neuromodulation Competitiveness Minimally Invasive Decompression and Surgical Treatment Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Sciatica Type, Pharmacological Therapy, Non-Pharmacological Treatment Modality, Route of Administration, End User, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Clinical, Therapeutic, and Treatment Pathway Analysis Technology Adoption Trends Across Physical & Exercise Therapy, Epidural Steroid Injections, Radiofrequency Ablation & Spinal Cord Stimulation, and Surgical Interventions List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Sciatica Type, Pharmacological Therapy, Non-Pharmacological Treatment Modality, Route of Administration, and End User (2025 vs. 2032) Global Sciatica Treatment Ecosystem and Value Chain Analysis